A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: Does nursing play a role?

Issues in Mental Health Nursing

Volumn 25, Issue 7, 2004, Pages 715-722

  Strinko, Janice M ^a,b   Di Bisceglie, Adrian M ^a   Hoffmann, Joyce A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CITALOPRAM; PAROXETINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SERTRALINE;

ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLAUSTROPHOBIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE REDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; IRRITABILITY; MOOD DISORDER; NONHUMAN; NURSING; PATIENT COMPLIANCE; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; CLINICAL NURSING RESEARCH; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MOOD DISORDERS; NURSING ASSESSMENT; NURSING DIAGNOSIS; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 4644338763     PISSN: 01612840     EISSN: None     Source Type: Journal    
DOI: 10.1080/01612840490486782     Document Type: Article

References (15)

1. Centers for Disease Control, National Institutes of Health, Consensus Development Conference Statement; Management of Hepatitis C: 2002. (2002, June 10-12). Retrieved July 21, 2003, from http://consensus.nih.gov/cons/116/ Hepc091202.pdf
2. Dierperink, E., Ho, S. B., Thuras, P., & Willenbring, M. L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 44(2), 104-112.
3. El-Serag, H. B., Kunik, M., Richardson, P., & Rabeneck, L. (2002). Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 123(2), 467-482.
4. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., & Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347(13), 975-982.
5. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., Meyers, C. A., & Howell, C. D. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7(9), 942-947.
6. Johnson, M. E., Fisher, D. G., Fenaughty, A., & Theno, S. A. (1998). Hepatitis C virus and depression in drug users. American Journal of Gastroenterology, 93(5), 785-789.
7. Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2002). Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 16(6), 1091-1099.
8. Kyngas, H. A. (2000). Nurses' support: Essential factor for the good compliance of adolescents with asthma. Nursing and Health Sciences, 2(4), 211-216.
9. Leone, N. E. (2002). The role of nursing in managing treatment-associated adverse effects in patients with hepatitis C. Gastroenterology Nursing, 25(5), 201-203.
10. Morgan, L. (2000). A decade review: Methods to improve adherence to the treatment regimen among hemodialysis patients. Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association, 27(3), 299-304.
11. National Digestive Diseases Information Clearinghouse. (2003, February). Chronic Hepatitis C: Disease Management. Treatment Section. NIH Publication No. 03-4230. Retrieved July 21, 2003, from http://www.niddk.nih.gov/health/digest/ pubs/chrnhepc/chrnhepc.htm#H
12. Roche Pharmaceuticals. (2002). Copegus (ribavirin, USP) tablets. Package insert. Roche Laboratories, Inc., Issued, December 2002.
13. Sivesind, D., & Baile, W. F. (2001). The psychologic distress of patients with cancer. Nursing Clinics of North America, 36(4), 809-825.
14. Trask, P. C., Esper, P., Riba, M., & Redman, B. (2000). Psychiatric side effects of Interferon therapy: prevalence, proposed mechanisms, and future directions. Journal of Clinical Oncology, 18(11), 2316-2326.
15. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-alpha therapy. Seminars in Oncology, 25(Suppl 1), 39-47.